^
Association details:
| Biomarker: | CD19 positive + CD20 positive |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug Class: | CD19-targeted CAR-T immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A NOVEL CD19/CD20 DUAL SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR (STAR) T CELL THERAPY FOR REFRACTORY AND RELAPSED (R/R) B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Published date:
05/12/2021
Excerpt:
Ten R/R patients with either CD19+ or CD19/CD20+ B-ALL were enrolled (median age of 23 years [11-55])....9/10 patients received a single infusion of dual STAR-T at a median dose of 1×106/kg (6 of 1×106/kg and 3 of 2×106/kg)...The CD19/CD20 STAR-T demonstrated technical feasibility and the ability to achieve a high CR with low toxicity in a phase I study of R/R B-ALL.
Trial ID:
